ArticleTranslational lung cancer research2019
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Article in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.International journal of clinical pharmacy · 2022Pooled it
- Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.Frontiers in pharmacology · 2022Pooled it
- Anlotinib combined with chemoradiotherapy for postoperative isolated lymph node recurrence of ESCC: a phase II study.Frontiers in immunology · 2026Trial
- Chemotherapy-free anlotinib-based regimens in advanced non-small cell lung cancer: a real-world retrospective cohort study.Journal of thoracic disease · 2026Article
- Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Efficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.Molecular and clinical oncology · 2025Article
- Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study.The clinical respiratory journal · 2025Article
- Case Report: A rare case of giant gallbladder associated with adverse reactions to anlotinib.Frontiers in medicine · 2025Article
- Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.International journal of general medicine · 2023Article
- Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial.JTO clinical and research reports · 2022Article
- Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.OncoTargets and therapy · 2022Article
- Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.Frontiers in oncology · 2022Article
- Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study.The Journal of international medical research · 2021Article
- Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.Journal of clinical laboratory analysis · 2021Article
- Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.Translational lung cancer research · 2021Article
- In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.Thoracic cancer · 2021Article
- [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- [Research Progress of Small Molecule Anti-angiogenic Drugs in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Article
- A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains one of the deadliest cancers worldwide. The ALTER0303 trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell lung cancer (NSCLC) patients. Meanwhile, the impact of previous therapy strategies on the efficiency of anlotinib still remains unknown.
methodsThe subgroup of patients in ALTER0303 were analyzed by using Kaplan-Meier estimates, Pearson χ
resultsThere was no statistical significance on progression-free survival (PFS) and overall survival (OS) among patients in different previous antiangiogenic treatments groups. Patients in the chest radiotherapy (CRT) group had longer median PFS than the non-CRT group (5.93
conclusionsThis study indicated that previous bevacizumab or endostatin treatments had no impact on the efficiency of anlotinib. Patients with CRT history benefited more from anlotinib on PFS. EGFR TKI and chemotherapy treatment history had more impact on OS than PFS in patients treated with anlotinib compared to placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.